SUPPORTIVE THERAPY FOR CHEMOTHERAPY-INDUCED NEUTROPENIA
نویسندگان
چکیده
منابع مشابه
Pegfilgrastim for chemotherapy-induced neutropenia.
Many chemotherapy regimens cause myelosuppression, which can result in febrile neutropenia and potentially lead to serious infections. The risk of neutropenia and its complications can be reduced with filgrastim, a granulocyte-colony-stimulating factor. Filgrastim is safe and effective, but it is cleared rapidly from the body (predominantly through the kidneys) and requires daily administration...
متن کاملRisk models for predicting chemotherapy-induced neutropenia.
Neutropenia and its complications, including febrile neutropenia, are major dose-limiting toxicities of systemic cancer chemotherapy. A number of studies have attempted to identify risk factors for neutropenia and its consequences to develop predictive models capable of identifying patients at greater risk for such complications and to guide more effective and cost-effective applications of the...
متن کاملChemotherapy in the elderly: supportive measures for chemotherapy-induced myelotoxicity.
Not only is the U.S. populace aging, but the incidence of cancer in the elderly also is increasing. Many elderly patients with cancer can obtain the same benefits from standard chemotherapy as younger patients can, but the elderly are more susceptible to the myelotoxicity of chemotherapy, which can limit the dose intensity of their treatments. Nurses can help identify patients at risk before th...
متن کاملChemotherapy induced febrile neutropenia: management and prevention.
chemotherapy remains the cornerstone of cancer therapy. In most cases bone marrow suppression represents the doselimiting toxicity of these drugs. Druginduced DNA damage at the level of bone marrow progenitor cells results in a fall in circulating neutrophil count. Patients with neutropenia are at increased risk of infection and sepsis.1 The timing of neutropenia is generally predictable; it ty...
متن کاملColony-stimulating factor therapy and febrile neutropenia induced by chemotherapy: need for economical studies.
Febrile neutropenia is the major dose-limiting toxicity of anticancer chemotherapy in small cell lung cancer (SCLC). Nadir and duration of neutropenia have been correlated to the risk of developing sepsis [1], increasing healthcare costs and deteriorating quality of life. Despite empirical broad-spectrum antibiotic therapy at the onset of fever and dose reduction of chemotherapy during subseque...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The KITAKANTO Medical Journal
سال: 1990
ISSN: 0023-1908,1883-6135
DOI: 10.2974/kmj1951.40.211